DRG Market Assessment 보고서

The irritable bowel syndrome (IBS) market has experienced slow growth owing to a lack of disease understanding, low rate of patients seeking treatment, and few effective therapies that treat all…

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with…

In 2017, branded biologic sales in oncology, immunology, endocrinology, and nephrology across the major markets exceeded $80 billion. Sales from biosimilars in the same therapy areas and regions…

Rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have…

Market Outlook Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances. Owing to these advances,…

Market Outlook: NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience…

Market Outlook Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’…

Market Outlook Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets…

The Alzheimer’s disease (AD) market today comprises a handful of symptomatic options that offer only modest efficacy of limited duration, leaving ample room for novel, more-effective alternatives…

Market Outlook The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGRP monoclonal antibodies (MAbs) in the United States in 2018, with a fourth to…

Myelofibrosis is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and splenomegaly…